Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HCV: DAA Treatment Linked to Reduced Diabetes Risk

Publish date:: March 8, 2019

Key clinical point: Study provides further evidence that DAA treatment has non–liver related benefits.

Major finding: DAA treatment was linked to lower diabetes incidence (HR, 0.48).

Study details: Propensity-matched, retrospective analysis (26,043 pairs).

Disclosures: The study was funded by Gilead. Dr. Butt has had research grants from Gilead and Dr. Schooley is on Gilead’s scientific advisory board.

Citation:

A Butt et al. CROI 2019. Abstract 88.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

Empagliflozin cut PA pressures in heart failure patients,